Infectious disease diagnostics Global Market estimated to be worth $26.0 billion by 2027
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi and these diseases can be spread, directly or indirectly, from one person to another. Some of the major infectious diseases are Viral (Hepatitis C, Hepatitis B, Human papillomavirus (HPV), HIV-1, Influenza, Dengue, Herpes Simplex Virus), Bacterial (Treponema Pallidum, Staphylococcus aureus, Chlamydia trachomatis and Neisseria gonorrhoeae, Streptococcus (A & B), Gardnerella vaginalis, Clostridium Difficile, MRSA, Tuberculosis), Fungal (Candida, Aspergillus) and other infections. There is an emerging trend towards precision health in today’s world to enhance disease diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies. Infectious disease diagnostics (IDDs) are a set of techniques used to analyze and detect the presence of pathogenic microorganisms using diagnostic tools like molecular diagnostics, immuno-diagnostics, mass spectroscopy and others.
The infectious disease diagnostics global market is expected to reach $26,028.0 million by 2027 growing at a low single digit CAGR from 2020 to 2027. Some of the factors such as the increasing prevalence of infectious diseases, the requirement of early detection for infectious disease, increasing point of care diagnostics and rapid diagnostics, favorable reimbursements, technological advancements and rising investments in diagnostics are driving the market. Whereas, lack of reproducibility and repeatability, high cost of infectious disease diagnostics products, lack of skilled professionals, stringent and time-consuming regulatory guidelines are some of the factors hindering the growth of the market.
The infectious disease diagnostics global market based on product is segmented into consumables, instruments, and software & services. The consumable segment accounted for the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027. The infectious disease diagnostics global market based on technology is segmented into immunodiagnostics, molecular diagnostics, and others. Among these, the immunodiagnostics segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The molecular diagnostics segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the increasing prevalence of infectious diseases and technological advancements.
Among various molecular diagnostics technologies, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious disease, technological advancements and rise in the number of diagnostic centers and hospitals are driving the PCR market. The NGS segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the advancements and declining costs of NGS platforms and improving regulatory and reimbursement scenario for NGS based diagnostic tests. Among various immunodiagnostics technology, the Lateral Flow Immunochromatography Assay (LFIA) segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious diseases, increase in demand for home-based lateral flow assay test kits and surge in demand for point-of-care testing are driving the market. The Enzyme Immunoassay (EIA) segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the increasing incidence of infectious diseases and increasing demand for cost-effective EIA test kits for diagnosis for various infectious diseases.
Infectious Disease Diagnostics global market based on application is segmented into a bacterial infection, viral infection, fungal infection, and others. Among these applications, viral infection diagnostics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to rising prevalence of HIV, hepatitis, influenza, rubella, increasing demand for more rapid diagnostic test kits for influenza and rising adoption of diagnostic kits for viral infections by physicians.
Infectious Disease Diagnostics global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) & clinics, centralized laboratory & clinical trials, academics & research institutes, and others. Among end-users, the hospitals, ASCs & clinics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Centralized Laboratories segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.
Infectious Disease Diagnostics global market based on mode of the test is segmented into centralized laboratories and Point-of-care (POC). Among these, the centralized laboratories segment holds the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The POC segment holds the second largest revenue in 2020 due to the rising prevalence of infectious diseases, technological advancements in POC testing products and growing patient awareness of POC testing are some of the major factors driving the POC market. Point of care tests (POCT), also called near-patient testing or bedside testing, refers to the performance of diagnostic tests at or near the site where the patient is located and helps in obtaining accurate results in a very short period of time, enabling clinicians to support the timely diagnosis, monitoring, and treatment of patients.
The infectious disease diagnostics market based on region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world. North America holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 mainly due to the adoption of the advanced technologies, presence of a highly developed healthcare system, increasing incidence of infectious diseases like Hepatitis, influenza and HIV, the presence of a large number of leading national clinical laboratories, increasing reimbursement scheme by the government, product launches, skilled personnel, investments, and funds. The Asia-Pacific region is the fastest-growing region growing with a strong mid single digit CAGR from 2020 to 2027 due to the increasing healthcare awareness, increasing prevalence of influenza, malaria and TB, government funding in developing countries.
Considering the attractiveness of the infectious disease diagnostics market, several venture capitalists are aggressively investing. Globally funding is more concentrated on bacterial and viral infection. For instance, in February 2020, Karius, Inc., Company received a fund amount of $165.0 million from SoftBank's Vision Fund, General Catalyst, HBM Healthcare, Khosla Ventures, and LightSpeed Venture Partners. The company plans to use the funding to expand its reach and also support future clinical studies. Karius test is used in more than 100 hospitals and health systems nationwide. It is designed to detect over 1,000 clinically relevant pathogens including bacteria, DNA viruses, fungi and parasites along with genomics and artificial intelligence technology, from a single blood draw.
In infectious disease diagnostics global market by mode of transmission, the sexually transmitted disease segment accounted for the largest share followed by airborne infection, hospital-acquired infection, vector-borne infection, waterborne infection, soil-transmitted infection and others in 2020. According to IQ4I analysis, globally there are approximately 505 million HIV tests, 92 million Tuberculosis tests, 366 million Malaria tests and 472 million Corona tests are performed annually.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment. According to the WHO, till August 6th, 2020, there were approximately 19.0 million coronavirus cases reported globally with 0.7 million deaths, and 12.2 million were recovered from this virus. The coronavirus is affecting 210 countries and territories around the world. According to IQ4I analysis, in 2020, it is estimated that a total of 472.3 million corona diagnostics test kits will be used globally to confirm the coronavirus cases. The average selling price of kit varies from one region to another with screen tests ranging from $10 to $40 and the confirmatory tests ranging from $30 to $90.
The infectious disease diagnostics companies are mainly focusing on expansion, new product launches, product approval, and acquisitions to be competent and gain access to new technologies both in existing and new market areas. For instance, in December 2019, Roche Ltd. launched cobas Zika test for use on the cobas 6800/8800 systems. The cobas Zika test detects Zika virus RNA in samples of human plasma and is intended for use in screening blood donations.
In April 2020, BD and BioGX Inc. have received Emergency Use Authorization (EUA) from USFDA for new diagnostics tests that would increase the potential capacity of the screen for COVID-19 by thousands of tests per day. In May 2020, Thermo Fisher Scientific Inc. received a contract from the U.S. government to provide highly specialized viral transport media (VTM) for COVID-19 sample collection. The VTM is used during the collection of patient samples for proper transport to laboratories that can test for the presence of the virus.
The infectious disease diagnostics global market is consolidated with the top ten players occupying major share of the market. Some of the major players in the market include Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), Danaher Corporation (U.S.), BioMerieux SA (France), Hologic, Inc. (U.S.), Bio-Rad Laboratories (U.S.), F. Hoffman-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Qiagen N.V (Netherlands), Diasorin, Inc. (U.S.) and Quidel Corporation (U.S.).